Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.
Back to Search Results

Connection

Search Results to Frits Van Rhee

This is a "connection" page, showing the details of why an item matched the keywords from your search.

                     
                     

One or more keywords matched the following items that are connected to Van Rhee, Frits

Item TypeName
Concept Patient Safety
Academic Article A phase 2, open-label, multicenter study of the long-term safety of siltuximab (an anti-interleukin-6 monoclonal antibody) in patients with multicentric Castleman disease.
Grant UARK 2002-36, An Open Label, Phase I Extension Study to Assess the Long-Term Safety and Tolerability of MRA as a Treatment for Castleman’s Disease
Grant A phase I/II open-label, dose escalation study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK525762 in subjects with
Grant A Phase 1/2 Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Subjects with Relapsed or Refractory Multiple Myeloma
Grant A Phase I/IIa Randomized, Observer-Blind, Placebo-Controlled, Multicenter Study to evaluate the Safety and Immunogenicity of the GSK Biologicals’ Herp
Grant A Randomized, Double blind, Placebo controlled Study to Assess the Efficacy and Safety of CNTO 328 (Anti IL 6 Monoclonal Antibody) Plus Best Supportiv
Grant Protocol CNTO328MCD2002; Phase 2, An Open-label, Multicenter Study to Evaluate the Safety of Long-term Treatment with Siltuximab in Subjects with Mult
Academic Article Long-term safety of siltuximab in patients with idiopathic multicentric Castleman disease: a prespecified, open-label, extension analysis of two trials.
Grant A Phase 1/2 Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Subjects with Relapsed or Refractory Multiple Myeloma
Grant A Phase I/IIa Randomized, Observer-Blind, Placebo-Controlled, Multicenter Study to evaluate the Safety and Immunogenicity of the GSK Biologicals’ Herp
Grant A Randomized, Double blind, Placebo controlled Study to Assess the Efficacy and Safety of CNTO 328 (Anti IL 6 Monoclonal Antibody) Plus Best Supportiv

Search Criteria
  • Safety